Key points are not available for this paper at this time.
Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC, a prospective observational 3-year study (CTRI/2017/05/008452), of participants with T2D on ≥2 antihyperglycemic medications. This subgroup analysis included 6222 participants, comprising 3517 men and 2705 women. The mean (SD) duration of T2D was 8.72 (5.8) years in men and 8.42 (5.4) years in women. At baseline, 1935 (75.4%) men and 1412 (74.4%) women had HbA1c ≥ 7%, which dropped to 1298 (63.0%) men and 1046 (63.8%) women at 3-year. The mean HbA1c, FPG, and PPG improved from baseline to 3-year in both genders (Table). The mean (SD) basal insulin dose reduced from 24.1 (19.1) U at baseline to 23.3 (16.3) U at 3-year in men and from 24.4 (18.7) U at baseline to 23.8 (16.2) U at 3-year in women. At 3-year, the most common macrovascular complication was myocardial infarction in men and peripheral vascular disease in women. Neuropathy was the most common microvascular complication in both genders at 3-year (Table). Hypertension and dyslipidemia were the most common CV risk factors reported at 3-year in both genders. This pivotal understanding of anthropometry, glycemic parameters, complications, and CV risk factors among genders may help strategize future diabetes management practices in India. Disclosure A.K. Das: Other Relationship; Sanofi. H. Thacker: Other Relationship; Merck Sharp Novo Nordisk. Speaker's Bureau; Novo Nordisk. Advisory Panel; Biocon. Speaker's Bureau; Biocon. Advisory Panel; Eris Lifesciences Ltd. Speaker's Bureau; Eris Lifesciences Ltd. Advisory Panel; Torrent Pharmaceuticals Ltd. Speaker's Bureau; Torrent Pharmaceuticals Ltd. Advisory Panel; USV Private Limited, Lupin Pharmaceuticals, Inc. A. Unnikrishnan: Speaker's Bureau; Sanofi. Other Relationship; Novo Nordisk. Speaker's Bureau; AstraZeneca, Boehringer-Ingelheim, Abbott, Intas Pharmaceuticals Ltd. Research Support; Torrent Pharmaceuticals Ltd. S. Wangnoo: None. S.K. Menon: Employee; Sanofi. A. Gadekar: None. D. Chodankar: Employee; Sanofi. Funding Sanofi
Das et al. (Fri,) studied this question.